Automated Stem Cell Factory
Readiness
TRL 6 · SRL 4 · gap +2
Gap = technical readiness − societal readiness. Positive: the technology is ready and society is not. Negative: society wants it more than the technology can deliver.
Not scored. Watchlist entries do not enter any gradient.
Robotics, imaging and process control applied to stem cell culture — growing, differentiating and quality-checking cells at industrial scale rather than by hand in a laboratory.
This is the least glamorous entry in the Human Expansion cluster and the one most likely to decide whether the others arrive. Cell therapies work in trials and remain extraordinarily expensive, and a large part of that cost is that the manufacturing is artisanal: skilled people, manual steps, batch variability, and a product that cannot be inventoried.
Technical readiness 6 against societal readiness 4. The gap is regulatory rather than public. A cell therapy's manufacturing process is part of what is approved, so changing it — automating it — means revisiting an approval. That is Chapter 17's pattern precisely: a rule written for a reason, still in force, now making the thing it governs more expensive than it needs to be.
Common misconception: that cost falls with demand here. Without automation it does not, because the input that scales is trained human hours.
What it does
mechanism — not yet written. Published as missing rather than hidden.